Old West Investment Management LLC Purchases New Stake in Core Laboratories Inc. $CLB

Old West Investment Management LLC purchased a new stake in shares of Core Laboratories Inc. (NYSE:CLB) in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 59,910 shares of the oil and gas company’s stock, valued at approximately $698,000. Old West Investment Management LLC owned about 0.13% of Core Laboratories at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in CLB. Goldman Sachs Group Inc. raised its position in shares of Core Laboratories by 185.0% in the fourth quarter. Goldman Sachs Group Inc. now owns 845,251 shares of the oil and gas company’s stock valued at $13,549,000 after purchasing an additional 548,657 shares during the period. Disciplined Growth Investors Inc. MN lifted its stake in shares of Core Laboratories by 9.7% during the 3rd quarter. Disciplined Growth Investors Inc. MN now owns 5,969,860 shares of the oil and gas company’s stock worth $73,787,000 after buying an additional 528,976 shares during the last quarter. Bank of New York Mellon Corp bought a new stake in shares of Core Laboratories during the 2nd quarter worth about $4,675,000. MAC Alpha Capital Management LP bought a new stake in shares of Core Laboratories during the 4th quarter worth about $5,016,000. Finally, Heartland Advisors Inc. acquired a new position in Core Laboratories in the 1st quarter valued at about $2,518,000. 97.81% of the stock is owned by institutional investors.

Core Laboratories Stock Up 0.2%

CLB opened at $12.48 on Monday. Core Laboratories Inc. has a fifty-two week low of $9.79 and a fifty-two week high of $20.36. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.55 and a current ratio of 2.12. The company has a market capitalization of $572.54 million, a P/E ratio of 22.28, a P/E/G ratio of 3.00 and a beta of 1.03. The stock has a fifty day moving average of $11.60 and a 200-day moving average of $14.67.

Core Laboratories (NYSE:CLB) last released its quarterly earnings results on Wednesday, July 29th. The oil and gas company reported $0.11 EPS for the quarter, beating the consensus estimate of $0.09 by $0.02. Core Laboratories had a net margin of 5.10% and a return on equity of 10.03%. The business had revenue of $124.61 million for the quarter, compared to the consensus estimate of $126.26 million. During the same period in the prior year, the company posted $0.19 earnings per share. Core Laboratories’s revenue was down 4.3% compared to the same quarter last year. Core Laboratories has set its Q3 2026 guidance at 0.120-0.200 EPS. On average, equities analysts expect that Core Laboratories Inc. will post 0.53 EPS for the current year.

Core Laboratories Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, August 31st. Shareholders of record on Monday, August 10th will be issued a $0.01 dividend. The ex-dividend date of this dividend is Monday, August 10th. This represents a $0.04 dividend on an annualized basis and a yield of 0.3%. Core Laboratories’s payout ratio is currently 7.14%.

Insider Activity

In other Core Laboratories news, CEO Lawrence Bruno bought 5,000 shares of the firm’s stock in a transaction on Friday, July 31st. The shares were purchased at an average price of $10.78 per share, for a total transaction of $53,900.00. Following the transaction, the chief executive officer directly owned 262,438 shares in the company, valued at approximately $2,829,081.64. This trade represents a 1.94% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 1.26% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several research firms have weighed in on CLB. Johnson Rice raised shares of Core Laboratories from a “hold” rating to a “buy” rating and set a $21.00 price target on the stock in a report on Thursday. Wall Street Zen upgraded Core Laboratories from a “sell” rating to a “hold” rating in a report on Saturday, August 1st. Finally, Weiss Ratings raised Core Laboratories from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, August 3rd. One investment analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $21.00.

About Core Laboratories

Core Laboratories N.V. is a global provider of proprietary and patented reservoir description and production enhancement services to the oil and gas industry. The company applies specialized expertise in core and fluid analysis, advanced petrophysical interpretation, and reservoir engineering to optimize hydrocarbon recovery. By integrating laboratory testing with field services and digital analytics, Core Laboratories delivers insights that help operators maximize production and extend the life of their assets.

The company’s portfolio spans two primary service lines: reservoir description and production enhancement.